Formula: C3H6O2In 2021 ,《Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation》 appeared in Chemical Biology & Drug Design. The author of the article were Liu, Juan; Zhang, Yuan; Huang, Honglin; Lei, Xiaoyong; Tang, Guotao; Cao, Xuan; Peng, Junmei. The article conveys some information:
A review. BCR-ABL is a gene produced by the fusion of the bcr gene and the c-abl proto-oncogene and is considered to be the main cause of chronic myelogenous leukemia (CML) production Therefore, the development of selective Bcr-Abl kinase inhibitors is an attractive strategy for the treatment of CML. However, in the treatment of CML with a Bcr-Abl kinase inhibitor, the T315I gatekeeper mutant disrupts the important contact interaction between the inhibitor and the enzyme, resistant to the first- and second-generation drugs currently approved, such as imatinib, bosutinib, nilotinib, and dasatinib. In order to overcome this special resistance, several different strategies have been explored, and many mols. have been studied to effectively inhibit Bcr-Abl T315I. Some of these mols. are still under development, and some are being studied preclinically, and still others are in clin. research. Herein, this review reports some of the major examples of third-generation Bcr-Abl inhibitors against the T315I mutation. In the experiment, the researchers used many compounds, for example, Oxetan-3-ol(cas: 7748-36-9Formula: C3H6O2)
Oxetan-3-ol(cas: 7748-36-9) is used as a reagent in the synthesis of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists. It is also used as a reagent in the synthesis of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors.Formula: C3H6O2
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts